8 results about "Dose group" patented technology

The invention belongs to the technical field of medical data processing, and discloses a multi-drug combined dose dynamic optimization method, equipment and a medium. The method comprises the following steps: constructing a multi-drug time-varying structure causal diagram; based on historical clinical observation data, performing causal effect learning on the structural causal diagram; in response to the current state input of a patient to be treated, carrying out anti-factual reasoning on the structure causality graph; an optimal dose combination is calculated that maximizes the desired efficacy and minimizes the uncertainty. According to the method, the structural causal diagram is constructed, the physiological state of the patient, multi-drug dose intervention, the pharmacokinetic process and the clinical outcome are uniformly modeled in the same causal framework, and the causal influence of the drug dose on the clinical outcome and the non-causal association relationship can be distinguished under the condition that historical clinical observation data are mixed and biased; and on this basis, anti-factual reasoning is performed on different dose combinations, so that potential clinical outcome distribution under assumed intervention conditions is obtained.

The invention discloses an application of pegylated irinotecan in preparation of a medicine for preventing and / or treating triple-negative breast cancer brain metastasis diseases, which is shown by in-vivo imaging observation and lifetime observation of high, medium and low dose groups of pegylated irinotecan with a specific structure. The high-dose group, the medium-dose group and the low-dose group all have a definite anti-tumor effect, bioluminescence signal values are inhibited to different degrees, the lifetime is prolonged, and the lifetime of the high-dose group and the lifetime of the medium-dose group are remarkably longer than that of the NKTR-102 group.

This disclosure relates to a method for determining bioeffective dose, wherein the method includes: detecting the boron concentration C of each voxel in the target at multiple time points. B ; Calculate C B The corresponding biological effect value (RBE) B Determine C B and RBE B The first association relationship, based on the first association relationship, determines the connection through C. B Characterized RBE B ; Calculate C B The corresponding first physical absorbed dose rate D B And other physical absorbed dose rates corresponding to dose components other than boron, and physical dose rate distribution D phy According to RBE B and D B The product of the other dose components and the product of other biological effect values ​​and other physically absorbed dose rates is used to calculate C. B The combined biological effect value (CBE); based on CBE and D phy Calculate the biologically effective dose D bio According to this disclosure, it is beneficial to determine the appropriate irradiation time for different voxels during BNCT in order to obtain better therapeutic effects.

The invention discloses an artificial intelligence-driven personalized drug dosage dynamic adjustment method and system. The method comprises the following steps: acquiring multi-source heterogeneous data of a patient, preprocessing and constructing to obtain graph structure data; performing feature extraction on the graph structure data by using a trained graph convolutional network to obtain high-order features of the patient, and predicting treatment conditions of the patient under different dose combinations; based on the high-order features, searching an optimal dose combination in a medication dose solution space by using an improved genetic algorithm, and generating a medication dose adjustment scheme; generating a risk assessment report based on the drug dosage adjustment scheme in combination with the multi-source heterogeneous data, and prompting the potential risk of dosage adjustment; and continuously collecting subsequent treatment feedback data of the patient and using the subsequent treatment feedback data to optimize the parameters of the graph convolutional network and the weight of the fitness function in the improved genetic algorithm. According to the method, the precision and dynamic adjustment of the medication dosage are realized.

The invention discloses application of hyperoside to treatment of endometriosis, and aims to evaluate whether hyperoside has an anti-fibrosis effect when applied to a rat endometriosis model by taking fibrosis as a treatment target. The method comprises the following steps: constructing a rat endometriosis model through an autotransplantation method, dividing molded rats into a low-dose group, a medium-dose group, a high-dose group, a model group and a western medicine control group 4 weeks after successful modeling, and laparotomizing and taking out ectopic lesions after respectively taking medicines for 4 weeks. HE staining and masson staining methods are used for mutually proving the fibrosis degree, the expression conditions of fibrosis indexes a-SMA, Co-1, CTGF and Fn are detected in an immunohistochemical mode, and the anti-fibrosis effect of hyperoside is evaluated. As a result, hyperoside can prevent the development of fibrosis in endometriosis, and thus hyperoside can be used as a drug for treating or preventing fibrosis in endometriosis.

The invention relates to the technical field of pharmacology, in particular to application of ursodesoxychoberberine to preparation of a medicine for preventing and / or relieving and / or treating pulmonary fibrosis. The preparation for preventing and / or relieving and / or treating pulmonary fibrosis is characterized in that the preparation contains ursodesoxychoberberine. The preparation also comprises one or more of a pharmaceutically acceptable carrier, an auxiliary material and an excipient. Dosage forms of the preparation include but are not limited to capsules, particles, tablets, pills, spray, suppositories, aerosols, powder aerosols, patches, oral liquid or injection. The indexes of a low-dose group and a high-dose group of the ursodesoxychoberberine are remarkably improved, the effect of the high-dose group is the best, and particularly, the high-dose group of the ursodesoxychoberberine is remarkably superior to that of a pirfenidone (PFD) positive drug group in the aspect of improving the body weight of a mouse. The results show that the ursodesoxychoberberine has a good development prospect as a candidate drug for resisting pulmonary fibrosis.

The present application relates to the technical field of pathological evaluation, and particularly relates to a heat stroke myocardial injury mouse model construction and evaluation method, comprising constructing a heat stroke myocardial injury mouse model by increasing the core body temperature, determining the key time point of the intervention effect of different dose gradients of GDF15 after the heat stroke modeling; obtaining the cTn-I index and the ALT index based on the key time point, determining the injury type ratio based on the normalized values of the cTn-I index and the ALT index to determine the injury type of the heat stroke; adjusting the evaluation strategy in response to the injury type, obtaining the recovery rate of the cTn-I index and the ALT index of the model control group at each time point to determine the myocardial injury degree and the liver injury degree at the corresponding time point; obtaining the average recovery rate of the ALT of each dose group to determine the ALT recovery rate ratio between different dose groups, and adjusting the observation length of the dose group. The present application can distinguish the injury types by constructing the heat stroke myocardial injury model, and cannot adapt to the dynamic changes of different injury types.

The invention belongs to the technical field of application of compound radix astragali oral liquid for strengthening the spleen, and particularly relates to application of the compound radix astragali oral liquid for strengthening the spleen in repairing digestive tract mucosal lesions of functional dyspepsia animals. Mucosal lesion, dysfunction and low-grade inflammation states are simulated. And randomly dividing the successfully molded rats into a model control group, a positive drug group and low, medium and high dose groups of the compound astragalus membranaceus spleen-tonifying oral liquid, and continuously performing intragastric administration for 21 days. Detection shows that the oral liquid can remarkably reduce the serum D-lactic acid level and the serum proinflammatory factor content, improve the pathological damage of stomach and duodenum tissues and improve the animal holding power. The invention provides a systematic method for evaluating that the oral liquid repairs the juvenile FD mucosal lesion, verifies the effects of enhancing the barrier and relieving inflammation, and also provides an effective tool for research and development of similar drugs.